BMS citizen petition
This article was originally published in The Tan Sheet
Executive Summary
Novartis Consumer Health has assumed ownership of a July 2001 citizen petition filed by Bristol-Meyers Squibb regarding use of 130 mg caffeine as an adjuvant to OTC analgesics, the firm informs FDA during a Jan. 19 teleconference. The petition is "still under review," according to FDA. Novartis has requested that it be allowed to meet with the Office of Nonprescription Products prior to the issuance of a response if the review findings are "not in favor" of the petition, according to minutes of the conference. The petition asks the agency to consider classifying caffeine 130 mg as Category I (safe and effective) when combined with aspirin or acetaminophen (1"The Tan Sheet" Aug. 13, 2001, p. 3). Novartis' purchase of Bristol's consumer unit - including caffeine-containing Excedrin - was announced in July 2005...
You may also be interested in...
Caffeine Dose Response Study To Support Category I Status Proposed By BMS
A placebo-controlled, dose-response trial comparing acetaminophen to combinations of caffeine with aspirin and acetaminophen has been proposed by Bristol-Myers Squibb.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.